EWTX8:00 AMEdgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026edgewisetx.com
EWTX8:00 AMEdgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indicationsedgewisetx.com
EWTX8:00 AMEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rulesedgewisetx.com
EWTX8:00 AMEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rulesedgewisetx.com
EWTX7:00 AMEdgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Upedgewisetx.com
EWTX8:00 AMEdgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026edgewisetx.com
EWTX8:00 AMEdgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conferenceedgewisetx.com
EWTX9:30 AMEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rulesedgewisetx.com